Composite Resins ; Dental Cements ; Dental Restoration, Permanent

Objective To explore the effect of type 2 diabetes mellitus(T2DM) on vascular damage characteristics of acute cerebral infarction and the impact on the short term prognosis.Methods One hundred and fifty-six cases of acute cerebral infarction patients were selected and divided into the T2DM group with 64 cases and non-T2DM group with 92 examples.According to the whole cerebral angiogram,the results and the results of the treatment of acute cerebral infarction and prognosis were analyzed.Results The incidence of intracranial artery stenosis of the T2DM group was 79.69％ (51/64),of non-T2DM group was 58.70％ (54/92),the difference between two groups was significant(x2=12.856,P＜0.05).The incidence of before andafter intracranial artery stenosis coexist,circulation narrow coexist in T2DM group was 50.00％ (32/64),59.36％(38/64) respectively,in non-T2DM group was 21.74％(20/92),29.35％(27/92) respectively,the difference between groups was significant(x2 =9.652,8.659;P＜0.05).The incidence of multivessel lesions and diffuse lesions and without collateral compensatory in T2DM group was 71.88％ (46/64),65.63％ (42/64) and 71.88％(46/64) respsctively,in non-T2DM group was 54.35％(59/92),39.13％(36/92) and 31.52％(29/92) respectively,thedifference between groups was significant(x2=8.625,9.354,11.053;P＜0.05).The total effective rate after 2 weeks of treatment in T2DM group was 46.88％(30/64),in non-T2DM group was 90.22％(83/92),the difference between groups was significant(x2=8.061,P＜0.05).Conclusion The incidence of intracranial artery stenosis in patients with intracranial artery stenosis combined with T2DM is higher than the control group,and lesion range widely,diffuse damage,vascular damage moderately severe stenosis and occlusion are significantly higher than in non-T2DM group,especially without collateral compensatory rates is higher than non-T2DM group,while the neural function damage of T2DM group is heavier and poorer prognosis.

Background Proliferative vitreo-retinal diseases include all the overly proliferative diseases of eyes.Many kinds of cytokines play important roles in their pathogenesis.Hypoxia-inducible factor 1α(HIF-1α)participates in the pathogenesis of a lot of ischemic diseases.HIF-1α may play an important role in the pathogenesis of proliferative vitreo-retinal diseases. Objective Present study was to observe the expression of HIF-1α in vitreous body in the eyes with proliferative vitreo-retinal diseases.The vitreous samples were collected during the vitrectomy from 71 eyes of 69 patients(experimental group)including 39 eyes with proliferative diabetic retinopathy(PDR)and 32 eyes with proliferative Vitreoretinopathy(PVR).Sixteen eyes of 16 patients as the cases control group,including 14 eyes with macular hole(MH)and 2 eyes with epiretinal macular membrane(ERM).What is more,there were 8 vitreous fluid samples of the normal control group.The concentrations of HIF-1α in vitreous body were detected by enzyme-linked immunosorbent assay(ELISA).The written informed consent was obtained from each patient before any medical procedure. Results The concentrations of HIF-1α in vitreous body in the eyes of experimental group,the cases control group and the normal control group were(294.08±2.97)、(260.41±8.29)、(16.38±3.56)mg/L respectively,showing a significant difference among the three groups(F=248.77,P=0.00).The concentrations of HIF-1α in vitreous body were obviously increased in the eyes of experimental group in comparison with the normal control group and the cases control group respectively(t=22.25,P=0.00;t=2.70,P=0.00 respectively).The concentrations of HIF-1α in vitreous body were increased in the eyes of the cases control group in comparison with the normal control group eyes(t=14.21,P=0.00).There was inferior correlation between the concentrations of HIF-1α in vitreous body in the eyes of experimental group and the course of ophthalmopathy. Conclusion Intravitreous HIF-1α level regulates in the eyes with proliferative vitreo-retinal diseases. Expression of HIF-1α in vitreous had inferior correlation with the course of ophthalmopathy. HIF-1α may play an important role in the pathogenesis of proliferative vitreo-retinal diseases.

Objective To research whether serum hepatocyte growth factor (HGF) level increases in ischemic stroke and hemorrhagic stroke, and explore the relationship between the serum HGF level and stroke recurrence. Methods We studied a total of 92 consecutive acute stroke patients who had been admitted to hospital within 24h of onset from 6 participating hospitals in Xi'an from January 2000 to May 2004. All patients were divided into ischemic stroke group and hemorrhagic stroke group according to the results of brain computed tomography (CT) scan or MRI on admission. Patients in stroke groups were divided into recurrent group and non-recurrent group. Healthy volunteers or patients without cerebrovascular diseases comprised the control group. Stroke and control groups were strictly matched with 1∶1 ratio. The patients were followed up for 4 years. Serum HGF was tested with enzyme-linked immunosorbent assay (ELISA). Results Serum HGF of stroke patients was significantly higher than that of control group (P<0.05). The serum HGF level in recurrent group was higher than that in non-recurrent group of ischemic patients, and there was no significant difference in hemorrhagic ones. Conclusion These results indicate that serum HGF may be used as a diagnostic marker for stroke, and serum HGF level is helpful in predicting the recurrence of ischemic stroke.

Humans ; Pulmonary Fibrosis ; metabolism ; pathology ; Signal Transduction ; physiology ; Transforming Growth Factor beta1 ; metabolism ; Wound Healing ; physiology

Adolescent ; Anemia, Aplastic ; complications ; Female ; Humans ; Lupus Erythematosus, Systemic ; complications

The purpose of this study was to investigate the pharmacokinetic interaction between sunitinib and ramipril in rats. Eighteen male SD rats were divided into three groups, with each group being assigned to orally receive sunitinib, ramipril, sunitinib and ramipril, respectively, for ten days. Blood samples were collected at dif-ferent times after first-day and tenth-day administration. The concentrations of ramiprilat and sunitinib in rat plasma were determined by LC/MS/MS and the pharmacokinetic parameters were calculated and statistically analyzed. Compared with the administration of ramipril alone, after a single-dose combined administration, tmax of ramiprilat decreased significantly and t1/2 prolonged, while AUC0-∞ remained unchanged. These results indicated that the ab-sorption rate of ramiprilat increased and the elimination rate decreased, but total absorption degree was not changed. After multiple-dose administrations, CL of ramiprilat decreased and AUC0-∞ increased obviously. It sug-gested that accumulation of ramiprilat occurred in body and the drug elimination became slower. No obvious difference of sunitinib pharmacokinetic behavior was found when it was given in combination with ramipril after a single-dose administration or multiple-dose administration. Sunitinib decreased the elimination of ramiprilat after co-administration in company with drug accumulation in body after multiple-dose co-administration. The study showed that there were pharmacokinetic interactions between sunitinib and ramipril in SD rats.

Objective To investigate the mRNA,protein expression and tyrosine phosphorylation of insulin receptor substrate.1(IRS-1)in endometrial carcinoma.Methods Sixty-three endometrial carcinoma(EC)patients,21 endometrial atypical hyperplasia(AHE)patients and 22 normal control(NE) entered this smdy.Their clinical information were colleeted Fasting serum C-peptide concentration was measured.Expression of IRS-1 in endometrium was examined by RT-PCR and western blol Immunoprecipitation was used to measure the tyrosine phosphorylation of IRS-1.Results C-peptide 0.007].There were no significant differences in IRS-l mRNA and protein expression among the three grouDs.Tyrosine phosphorylation of IRS-1 in EC group[(62±36)%]was higher than that in AHE and NE groups[(53 4-34)%and(35 4-33)%;P=0.048,0.002].IRS-1 activation in AHE group was also higher than nornlal control(P=0.045).IRs-1 activation in endometrioid carcinoma[(69 4-33)%]was higher than that in other histological types[(34±31)%;t=2.300,P=0.025].IRs-l tyrosine phosphorylation was significantly higher in patients with advanced stage,high grade,deep myometrial invasion and pelvic lymph node metastasis.IRS-l activation in endometrium was positively correlated with fasting sertlm C-peptide concentration(r=0.491,P=0.001).Conclusions There is excessive activation of IRS-1 in endometrial carcinoma and atypical hyperplasia.Activation of IRS-I in endometrial carcinoma is related with poor clinical-pathologic fleatures and may be a prognostic predictor for this tumor.Over-activationof IRS-1 may be an intermediate event linking the hyperinsulinemia and endometrial carcinoma.

China ; epidemiology ; Coal Mining ; Dust ; analysis ; Environmental Monitoring ; Epidemiological Monitoring ; Humans ; Pneumoconiosis ; epidemiology

Molecular target-based cancer therapy is playing a more and more important role in cancer therapy because of its high specificity, good tolerance and so on. There are different kinds of molecular targeted drugs such as monoclonal antibodies and small molecular kinase inhibitors, and more than 50 drugs have been approved since 1997. When the first monoclonal antibody, rituximab, was on the market. The development of molecular target-based cancer therapeutics has become the main approach. Based on this, we summarized the drugs approved by FDA and introduced their mechanism of actions and clinical applications. In order to incorporate most molecular targeted drugs and describe clearly various characteristics, we divided them into four categories: drugs related to EGFR, drugs related to antiangiogenesis, drugs related to specific antigen and other targeted drugs. The purpose of this review is to provide a current status of this field and discover the main problems in the molecular targeted therapy.
Angiogenesis Inhibitors ; Antibodies, Monoclonal ; Drug Delivery Systems ; Humans ; Molecular Targeted Therapy ; Neoplasms ; drug therapy ; Protein Kinase Inhibitors ; Receptor, Epidermal Growth Factor ; antagonists & inhibitors